11/16/2026 | Press release | Archived content
SINGAPORE - November 16, 2026 - Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has contributed insights to a newly published whitepaper by the Singapore Clinical Research Institute (SCRI). The paper, titled "Advancing Clinical Trials with Decentralised Elements in Singapore: Opportunities, Readiness, and Scalable Adoption," assesses Singapore's readiness for clinical trials with decentralised elements and outlines a roadmap for their responsible, scalable adoption.
Drawing on its experience supporting more than 42,000 global trials and 13 million patients, Medidata contributed global perspectives and practical insights to the whitepaper's assessment of Singapore's current ecosystem readiness. The paper concludes that while Singapore is well-positioned for selective adoption of decentralised elements in hybrid trials, achieving system-wide readiness requires moving from ad-hoc institutional arrangements to a standardised, scalable national operating model.
"Decentralised elements are increasingly incorporated into global protocol design, but their adoption must be grounded in fit-for-purpose operational models, robust data governance, and scalable technology," said Edwin Ng, General Manager, Asia Pacific, Medidata. "Drawing on Medidata's experience across thousands of global studies, our unified platform technology can support connected workflows and auditable data integrity in trials with decentralised elements, alongside appropriate validation and operational oversight. We are proud to contribute these insights to SCRI's whitepaper and to support sponsors, investigator sites, and patients in delivering safe, more accessible, and high-quality clinical research across Singapore and the broader region."
To support Singapore's transition from pilot implementations to scalable hybrid maturity, the whitepaper outlines several core national recommendations:
Unlocking Value for Asia-Pacific Clinical Research through this strategic collaboration, Medidata provided evidence-based insights to address bottlenecks across the clinical research ecosystem:
Singapore has established strong foundations in clinical research; the opportunity now is to build on these strengths through a greater ecosystem collaboration that enables the appropriate use of decentralised elements to improve patient access and strengthen trial delivery. "This whitepaper sets out a phased roadmap to help Singapore scale these approaches, enhance research efficiency, and strengthen Singapore's position as a trusted clinical research hub in Asia," said Adjunct Associate Professor Danny Soon, CEO, Consortium for Clinical Research and Innovation, Singapore (CRIS) and Executive Director, SCRI.
Learn more about the whitepaper here.
About Medidata
Medidata has been powering smarter treatments and healthier people by supporting clinical trials through groundbreaking technological innovations for over 25 years. Medidata is a leader in AI-powered solutions across the entire trial lifecycle to accelerate clinical breakthroughs, reduce patient and site burden, and bring new therapies to market faster. Supported by one of the largest clinical datasets in the industry of more than 42,000 trials and 13 million patients, Medidata's Study, Patient, and Data Experiences are trusted by more than 1 million registered users across approximately 2,300 customers. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and is recognized as a leader by Everest Group and IDC. Discover more at www.medidata.com. Listen to our latest podcast, from Dreamers to Disruptors, and follow us at @medidata-solutions on LinkedIn.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. Through the 3DEXPERIENCE agentic platform, AI-powered, science-based virtual twins help 390,000 customers of all sizes, in all industries, collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com
About the Singapore Clinical Research Institute
SCRI was established in 2008 as the national academic clinical research organisation to enhance the standards of clinical research in Singapore by developing core capabilities, infrastructure and scientific leadership for clinical research. In 2021, SCRI was appointed as the national coordinating body to implement the national clinical trial strategy and enhance Singapore's clinical trial ecosystem. This is accomplished through the deployment of innovative technologies and processes, and strategic coordination of ecosystem capabilities and infrastructure to achieve synergies that will enhance the clinical research ecosystem aimed towards a healthier community and better patient outcomes.
SCRI's key pillars include:
SCRI is a programme of the Consortium for Clinical Research and Innovation, Singapore (CRIS). SCRI is supported by the Singapore Ministry of Health through the NMRC Office, MOH Holdings Pte Ltd under the NMRC Industry Sponsored Trials (MOH-002073) and Core Funding for Clinical Research Enablers (MOH-002074) funding initiatives.
For more information, please visit https://www.scri.edu.sg/.
Contact:
For interviews and questions, please contact Medidata PR